Descriptor English: | Calcifediol | ||||||
Descriptor Spanish: |
Calcifediol
| ||||||
Descriptor Portuguese: | Calcifediol | ||||||
Descriptor French: | Calcifédiol | ||||||
Entry term(s): |
25 Hydroxycholecalciferol 25 Hydroxycholecalciferol Monohydrate 25 Hydroxyvitamin D 3 25 Hydroxyvitamin D3 25-Hydroxycholecalciferol 25-Hydroxycholecalciferol Monohydrate 25-Hydroxyvitamin D 3 25-Hydroxyvitamin D3 Anhydrous, Calcifediol Calcidiol Calcifediol Anhydrous Calcifediol, (3 alpha,5Z,7E)-Isomer Calcifediol, (3 beta,5E,7E)-Isomer Calderol Dedrogyl Hidroferol Monohydrate, 25-Hydroxycholecalciferol |
||||||
Tree number(s): |
D04.210.500.247.222.159.478.250 D04.210.500.247.808.146.478.250 D04.210.500.812.768.196.478.250 D10.570.938.146.478.250 |
||||||
RDF Unique Identifier: | https://id.nlm.nih.gov/mesh/D002112 | ||||||
Scope note: | The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. |
||||||
Annotation: | deficiency: coordinate CALCIFEDIOL /defic (IM) with VITAMIN D DEFICIENCY (IM) |
||||||
Allowable Qualifiers: |
AA analogs & derivatives AD administration & dosage AE adverse effects AG agonists AI antagonists & inhibitors AN analysis BI biosynthesis BL blood CF cerebrospinal fluid CH chemistry CL classification CS chemical synthesis DF deficiency EC economics GE genetics HI history IM immunology IP isolation & purification ME metabolism PD pharmacology PH physiology PK pharmacokinetics PO poisoning RE radiation effects SD supply & distribution ST standards TO toxicity TU therapeutic use UR urine |
||||||
Pharm Action: |
Vitamins Bone Density Conservation Agents |
||||||
Registry Number: | P6YZ13C99Q | ||||||
CAS Type 1 Name: | 9,10-Secocholesta-5,7,10(19)-triene-3,25-diol, (3beta,5Z,7E)- | ||||||
Previous Indexing: |
Cholecalciferols (1966-1972) Hydroxycholecalciferols (1972-1982) |
||||||
Public MeSH Note: | 83 |
||||||
History Note: | 83 |
||||||
DeCS ID: | 2146 | ||||||
Unique ID: | D002112 | ||||||
Documents indexed in the Virtual Health Library (VHL): | Click here to access the VHL documents | ||||||
Date Established: | 1983/01/01 | ||||||
Date of Entry: | 1982/05/04 | ||||||
Revision Date: | 2017/05/24 |
-
-
CHEMICALS AND DRUGS
Polycyclic Compounds [D04]Polycyclic Compounds -
CHEMICALS AND DRUGS
Polycyclic Compounds [D04]Polycyclic Compounds -
CHEMICALS AND DRUGS
Polycyclic Compounds [D04]Polycyclic Compounds -
CHEMICALS AND DRUGS
Lipids [D10]Lipids
|
Calcifediol
- Preferred
Calcifediol, (3 beta,5E,7E)-Isomer
- Narrower
Calcifediol Anhydrous
- Narrower
Dedrogyl
- Narrower
Hidroferol
- Narrower
Calcifediol, (3 alpha,5Z,7E)-Isomer
- Narrower
Calderol
- Narrower
Concept UI |
M0003141 |
Scope note | The major circulating metabolite of VITAMIN D3. It is produced in the LIVER and is the best indicator of the body's vitamin D stores. It is effective in the treatment of RICKETS and OSTEOMALACIA, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. |
Preferred term | Calcifediol |
Entry term(s) |
25 Hydroxycholecalciferol 25 Hydroxycholecalciferol Monohydrate 25 Hydroxyvitamin D 3 25 Hydroxyvitamin D3 25-Hydroxycholecalciferol 25-Hydroxycholecalciferol Monohydrate 25-Hydroxyvitamin D 3 25-Hydroxyvitamin D3 Calcidiol Monohydrate, 25-Hydroxycholecalciferol |
Concept UI |
M0330893 |
Preferred term | Calcifediol, (3 beta,5E,7E)-Isomer |
Concept UI |
M0585635 |
Preferred term | Calcifediol Anhydrous |
Entry term(s) |
Anhydrous, Calcifediol |
Concept UI |
M0462847 |
Preferred term | Dedrogyl |
Concept UI |
M0466590 |
Preferred term | Hidroferol |
Concept UI |
M0330894 |
Preferred term | Calcifediol, (3 alpha,5Z,7E)-Isomer |
Concept UI |
M0462848 |
Preferred term | Calderol |
We want your feedback on the new DeCS / MeSH website
We invite you to complete a survey that will take no more than 3 minutes.
Go to survey